Explorez tous les épisodes du podcast Docs Who Lift

Docs Who Lift finally got a big pharma exec on the show. Dr. Ken Custer is President of Lilly's Cardiometabolic Health, and he came straight from the EASD conference in Milan with fresh data on what's coming after tirzepatide.

If you've been waiting on retatrutide, this is the episode. Spencer and Karl get Custer to walk through the new phase 3 results and the tirzepatide plus eluralintide combination, including why stacking these mechanisms seems to deliver more than drug developers usually get. You'll hear how amylin works on a completely different set of brain pathways than GLP-1, why Lilly walked away from one version of the drug in favor of another, and what the early tolerability data looks like. That last part matters if you're one of the people who couldn't handle a GLP-1, or you've been too nervous to try one.

The conversation then opens up to the questions patients actually ask. What's next if you hit a wall on tirzepatide and still have weight to lose. Whether these medications will ever be approved for people who aren't sick yet, just heading that direction. And why it's getting harder to run trials at all when everyone can tell whether they're on the real drug.

The back half goes behind the curtain. Custer is honest about how often drug development fails, what these trials cost, and what it was like to be in the room the day Lilly chose tirzepatide, a molecule he's now spent 12 years on. He takes on the pricing question directly, explains where coverage is headed, and makes his case for why access is still the biggest problem.

It ends where you'd want it to. The gray market, what regulation actually gets you, and how to think about doctors who work with pharma versus the people calling them shills while selling supplements with zero data behind them.

Nobody got paid for this one.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. David Allison and Dr. Emily Dhurandhar join Dr. Spencer Nadolsky and Dr. Karl Nadolsky to break down their new research on food noise. Patients on GLP-1s kept describing the same thing: the constant background chatter about food finally went quiet. Allison and Dhurandhar convened an expert panel of physicians, psychologists, statisticians, and eating disorder specialists to define it properly and build a validated questionnaire to measure it.

Their definition: persistent, unwanted, unpleasant thoughts about food that harm your social, physical, or mental health. The data revealed three distinct parts. Preoccupation with food, how inescapable it feels, and how distressing it is. That third piece, the dysphoria, is what separates food noise from hunger and cravings. Cravings can be enjoyable. Food noise is not.

The conversation covers why food noise correlates with other appetite measures without being the same thing, patients who lose almost no weight on medication but refuse to stop taking it because of the mental relief, and whether food noise alone could justify treatment. They also share where the research is headed, from translations into ten languages and a new adolescent validation to a study testing whether food noise affects driving safety. And they answer the claim that Big Pharma invented the term.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Christian Rodriguez joins the show straight from Pennington Biomedical, where he works alongside obesity research legends Eric Ravussin and Steve Heymsfield. He breaks down his new review on metabolically healthy obesity and why the old "zero metabolic syndrome criteria" definitions are so inconsistent. The conversation dives deep into the Lancet Commission's new obesity framework, comparing it to the ACE staging system and picking apart where each one falls short, including the controversial call to leave type 2 diabetes out of the "preclinical" category. Rodriguez also previews his upcoming study on people with a BMI of 60 and above, a group that's rarely studied because researchers aren't sure it's safe. The episode wraps with a candid discussion on GLP-1 stigma and why treating obesity early matters more than chasing a number on the scale.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Could your weight gain and non-stop thoughts about food actually come from a rare condition you were born with? In this episode of the Docs Who Lift podcast, Dr. Spencer Nadolsky and Dr. Karl Nadolsky chat with weight expert Dr. Jesse Richards about Bardet-Biedl Syndrome (BBS). This rare condition tricks your brain into thinking your body is starving, even when you have plenty of body fat stored up.

They talk about how doctors figure out if someone has BBS, an easy math trick to check your risk, and why normal diets or standard weight-loss shots do not always work for this condition. Plus, you will learn about special medicines that fix the brain's hunger signals when nothing else seems to work!

What Bardet-Biedl Syndrome (BBS) is and why many doctors miss it.

Clear physical signs to look for, like extra fingers or toes, vision loss, and weight gain that starts very early in life.

An easy formula to check your risk using your weight and your daily thoughts about food.

The big difference between normal food cravings and extreme, non-stop hunger.

Why special medicines can fix brain signals when regular weight-loss tools fail.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode they cover why the name polycystic ovarian syndrome has been misleading from the start given that you do not need polycystic ovaries to have the condition and you can have polycystic ovaries without having the condition at all, what the Rotterdam criteria actually are and why having two of three features including irregular periods, elevated androgens, and polycystic ovarian morphology is enough for a diagnosis that covers a wide and sometimes contradictory range of presentations, why a group of international endocrinologists are pushing to rename the condition anovulatory androgen excess to center the diagnosis on the two features that actually matter clinically and remove the ovarian morphology criterion that causes the most confusion, what the four Rotterdam phenotypes look like and why phenotype D which has irregular periods and polycystic ovaries but no elevated androgens is the one the new criteria would exclude from the diagnosis entirely, why some patient advocates are pushing back on the rename out of concern that it erases a community identity that has been built around the PCOS name and what Spencer, Karl, and Dr. Brian think about that tension, how insulin resistance fits into the picture and why it is not part of the diagnostic criteria even though it is present in the majority of patients and drives most of the downstream metabolic risk, why metformin and GLP-1 medicines are doing a lot of heavy lifting for PCOS patients right now and how Dr. Brian approaches treatment decisions in clinical practice, what the data shows on inositol supplementation and why Dr. Brian has more time for it than she does for most supplements in this space, why the androgen piece is so frequently undertreated and how measuring free testosterone versus total testosterone changes what you see in the labs, how birth control fits into the treatment conversation and why it is both overused as a first line fix and genuinely useful when deployed correctly, and what women who have been told they have PCOS should actually be asking their doctor at their next appointment regardless of what the condition ends up being called.

The Docs Who Lift podcast distills and simplifies the complexities of exercise, medicine, and weight loss. Subscribe so you never miss an episode.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Spencer Nadolsky and Karl bring on Dr. Austin Baraki and Dr. Jordan Feigenbaum from the Barbell Medicine crew for a conversation that cuts through one of the most hyped and least understood topics in the health and fitness space right now: the research peptides that millions of people are injecting into themselves based on anecdotes, social media marketing, and the logic that short chain amino acids are natural so they must be fine.

In this episode they cover what peptides actually are from a basic biochemistry standpoint and why calling something a short chain amino acids does not make it a food or a supplement it makes it a drug with all the same questions around safety efficacy dosing and long-term effects that any other drug requires, why the explosion of GLP-1 popularity essentially normalized both injectable medications and the idea that if semaglutide works this well what else is out there leading directly to the current peptide boom, why BPC-157 has no randomized controlled trial data in humans and the three human trials that were started were all terminated early with results never published which is a red flag that would make people furious if it were a vaccine but barely registers in the peptide space, why TB-500 has wound healing data when applied topically but nothing when injected despite being universally marketed as a muscle and tendon healer, why MOTS-C has never been tested in humans at all and yet enormous numbers of people are currently injecting it, why the argument that big pharma would sell these if they worked is actually the correct argument and why most of these compounds were abandoned precisely because they failed in trials or showed harm signals, why biological plausibility is a dangerous standard to rely on given that suppressing arrhythmias seemed biologically obvious until the CAST trial showed it killed people and beta blockers for heart failure seemed obviously wrong until trials showed they were life saving, what a randomized controlled trial actually does that anecdote cannot and why thousands of positive experiences are not equivalent to controlled data, why a JAMA study on SARMs sold as research chemicals found that only 18 of 44 products actually contained what was on the label meaning people may not even be getting the compound they think they are getting, why the doctors on this podcast could have made millions of dollars branding and selling their own peptide lines and have specifically chosen not to, and what standard of evidence they believe should be the minimum before recommending any compound to another human being.

The Docs Who Lift podcast distills and simplifies the complexities of exercise, medicine, and weight loss. Subscribe so you never miss an episode.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Spencer and Karl Nadolsky sit down with David W, a nurse practitioner and one of the actual patients enrolled in the Triumph 1 retatrutide phase 3 trial, to break down the data that was just presented at the American Diabetes Association conference and explain why everyone in obesity medicine is paying very close attention.

In this episode they cover what retatrutide actually is and why adding glucagon agonism to the GLP-1 and GIP dual agonism of tirzepatide creates a meaningfully different drug with direct effects on liver lipid metabolism, insulin sensitivity, blood pressure, and fat catabolism that you do not see with semaglutide or tirzepatide alone, what David's personal experience in the 12 milligram arm looked like from dose escalation through steady state including the GI side effects that faded by month seven and the heartburn that a low dose PPI fixed quickly, how David went from 240 pounds and a BMI of 35 down to 167 pounds by the end of the trial representing roughly 30 percent weight loss which is right at the trial average, what the Triumph 1 obesity trial found at 80 weeks with the nine and 12 milligram doses delivering nearly 26 and 28 percent average weight loss respectively and almost half of patients on the highest dose losing 30 percent or more, why the 104 week extension data showing patients who stayed on 12 milligrams reaching 30.3 percent average weight loss is being compared to bariatric surgery outcomes, what the Transcend type 2 diabetes trial showed with average A1C dropping to 5.9 percent on the 12 milligram dose in patients who were on no other diabetes medication, why the 41 percent triglyceride reduction and 20 percent LDL reduction are particularly interesting given that the mechanism appears to involve multiple pathways in the liver that tirzepatide and semaglutide do not touch, what the 70 percent reduction in WOMAC knee arthritis pain scores and 60 percent reduction in sleep apnea events mean for patients who have been told their only option is surgery, how Spencer plans to use retatrutide clinically once it is approved and which patients he thinks are the right candidates, why the gray market research peptide version currently circulating is something both doctors strongly advise against, and what Triumph 2 and Triumph 3 are measuring and when that data is expected.

The Docs Who Lift podcast distills and simplifies the complexities of exercise, medicine, and weight loss. Subscribe so you never miss an episode.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Spencer Nadolsky and Karl break down two brand new randomized controlled trials that put hard numbers on a question they have been navigating clinically for years: what actually happens to patients on GLP-1 medicines when they try to lower their dose, switch to a cheaper option, or come off entirely.

In this episode they cover why obesity biology actively fights back against weight loss through hunger hormones, fat cell hormones, and hypothalamic signaling in ways that make maintenance genuinely hard for most people and not a failure of willpower, what the Surmount-4 trial showed about weight regain when people came off tirzepatide after losing an average of 21 percent of their body weight and why that 17 percent who maintained their weight off medication is a number that keeps showing up across multiple studies, what the brand new Surmount-Maintain trial did by reducing some patients from their maximum tolerated dose of tirzepatide down to five milligrams and what that meant for weight outcomes at 112 weeks, why the average line graph in these trials can make it look like everyone on the max dose kept their weight off when the waterfall plots tell a more complicated story with roughly 25 to 30 percent of people on the highest dose still not maintaining 85 percent of their weight loss, what rescue tirzepatide was and why two thirds of placebo patients needed it, what the Attain-Maintain trial tested by switching patients who finished Surmount-5 from tirzepatide or semaglutide over to orforglipron and whether an oral GLP-1 can hold the weight that an injectable one lost, why orforglipron is not yet cost efficient enough for most patients as a maintenance strategy despite the promising data, why Spencer and Karl both see fewer than five percent of their own patients regain significant weight on the maximum tolerated dose and what that gap between clinical experience and trial data might be telling us, the weight independent benefits of GLP-1 medicines including blood sugar control and cardiovascular effects that matter even if weight stays the same, and why people injecting unapproved research peptides like retatrutide without FDA approval or human safety data is something both doctors find genuinely alarming.

The Docs Who Lift podcast distills and simplifies the complexities of exercise, medicine, and weight loss. Subscribe so you never miss an episode.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Spencer Nadolsky and Karl sit down with Dr. Susan Brian, a Yale-trained endocrinologist, certified menopause provider, and medical director of a clinic with seven endocrinologists who runs an active bone fragility fracture clinic, to answer the question that has been flooding social media since a viral abstract with two fake bones on a surgical table convinced people their skeletons are quietly dissolving.

Follow Dr. Susan here

In this episode they cover why the preclinical and mechanistic data on GLP-1 medicines actually points toward bone benefit rather than harm by improving osteoblast activity and reducing osteoclast activity, why the meta-analyses from over two decades of GLP-1 use in type 2 diabetes show reduced fracture risk rather than increased risk, what the recent Israeli retrospective cohort study actually found and why an 11% increased fragility fracture signal in older adults on GLP-1 for diabetes versus other treatments deserves attention without panic, why almost every nutritional deficiency flagged in GLP-1 patients turns out to be vitamin D deficiency that likely predated the medicine, why the degree of weight loss matters far more than the medicine itself and how the one to two pounds per week threshold and the one percent of body weight per week guideline translate into real clinical practice, what the Hansen JAMA 2024 study showed about GLP-1 alone versus GLP-1 with resistance training and why that finding is the single most important takeaway for anyone on these medicines, why Spencer has idiopathic hypercalciuria and was spilling 650 milligrams of calcium per day in his urine before anyone caught it, how romosozumab works and why it is the most powerful bone building medicine available, why Dr. Brian orders baseline bone densities on patients well before the standard screening age and why insurance almost always covers it, and why comparing GLP-1 nutritional risk to bariatric surgery nutritional risk is not even close to an apples to apples comparison.

The Docs Who Lift podcast distills and simplifies the complexities of exercise, medicine, and weight loss. Subscribe so you never miss an episode.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Spencer Nadolsky and Karl sit down with Dr. Eryn Russo, a board-certified occupational and environmental medicine physician with nearly 20 years of experience working at Hill Air Force Base, where she deals with real toxic metal exposures every single day. She is one of less than one percent of all board-certified physicians practicing in this specialty, which makes her exactly the person you want explaining why the heavy metal detox content flooding your social media feed is not medicine. It is marketing.

In this episode they cover how a proper toxic exposure workup actually happens including detailed exposure history, industrial hygiene testing at the source, biological monitoring, and organ-specific testing that goes far beyond a urine panel mailed to your house, why the provoked urine test being sold by influencers is a complete artifact that artificially concentrates metals in your urine using the same chelation agent they then try to sell you as treatment, the real clinical presentations of lead, mercury, cadmium, arsenic, and chromium six and why none of them look like vague brain fog or fatigue, why the gold standard test for lead is blood not urine and what the actual diagnostic thresholds are for adults versus children, why amalgam fillings and the form of mercury previously used in vaccines are not the toxic forms people need to worry about, the Consumer Reports plant protein lead story and whether parents actually need to be concerned, why Dr. Russo has never once recommended chelation therapy in 20 years of treating workers who actually work with these chemicals daily, and why real chelation therapy carries serious renal and electrolyte risks that make unsupervised use genuinely dangerous.

The Docs Who Lift podcast distills and simplifies the complexities of exercise, medicine, and weight loss. Subscribe so you never miss an episode.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Spencer Nadolsky and Karl sit down with Dr. Adam Auton, geneticist at 23andMe, to break down a brand new paper using data from over 27,000 people that identified specific genetic variants linked to how well GLP-1 medications work and how likely someone is to experience side effects. 23andMe has over 11 million people in their research database and used voluntary survey data on medication use, dosage, duration, weight loss, and side effects to match against genetic profiles at scale, making this one of the most powerful datasets anyone has brought to this question.

In this episode they cover how genome-wide association studies work and why scanning 600,000 genetic variants at once lets researchers find signals they never could have predicted in advance, why the first signal that jumped out of the data was a variant right in the GLP-1 receptor itself and why that was the moment the team knew they were on the right track, why the same variant that predicts better efficacy also predicts a higher risk of side effects and what that tells us about how the drug is being processed, why tirzepatide users showed a separate signal in the GIP receptor that modulates side effects rather than weight loss, why carrying both variants could make someone 14 times more likely to experience side effects on tirzepatide, why genetics explains roughly 10 percent of weight loss variation and what the other 90 percent looks like, why women tend to respond better than men and why diabetics tend to respond less well, what the future of this research looks like including who regains weight after stopping and whether those patterns are genetically predictable, and why heritability is a statistical measure that gets badly misunderstood even by clinicians.

The Docs Who Lift podcast distills and simplifies the complexities of exercise, medicine, and weight loss. Subscribe so you never miss an episode.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

5:37 PM

Dr. Spencer Nadolsky and Karl sit down with Dr. Henning Langer, PhD researcher at the Charité in Berlin and founder of his own muscle metabolism lab, to break down his newly published paper combining rodent and human data to look directly at what GLP-1 medicines actually do to skeletal muscle beyond what a DEXA scan can tell you. Dr. Langer spent time at Boehringer Ingelheim specifically studying skeletal muscle during obesity and anti-obesity treatment before bringing that work to his own lab, and this paper is one of the only studies to date that has looked at muscle directly rather than lean body mass as a proxy.

In this episode they cover why the step one trial's 40 percent lean mass loss figure may not be as alarming as it sounds and why most incretin trials actually land closer to the expected 25 percent, why lean body mass on a DEXA scan conflates muscle with glycogen, liver weight, and water in ways that overstate actual muscle loss, why the mice on semaglutide that looked the roughest in their cage ran the best on the treadmill to exhaustion, what mitochondrial protein changes in the proteome data suggest about a possible fatigue resistance benefit that cannot be explained by fat loss alone, how absolute muscle force tended to drop slightly while relative strength and endurance held up, what the human data from Nottingham showed about maximum voluntary contraction and knee extension force in patients on GLP-1 treatment, why the geriatric population is the next big unanswered question in this space, and why resistance training combined with high protein still cuts muscle loss in half and remains the most powerful lever available regardless of what the pharmacology does.

The Docs Who Lift podcast distills and simplifies the complexities of exercise, medicine, and weight loss. Subscribe so you never miss an episode.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Spencer Nadolsky and Dr. Karl Nadolsky sit down with Dr. Stuart Phillips, senior author on the newly updated American College of Sports Medicine position stand on resistance training, to break down what 137 systematic reviews and over 30,000 participants actually tell us about building muscle, getting stronger, and improving function across the lifespan. The last version of these guidelines was published in 2009 and the science has come a long way, even if the fundamentals have not.

In this episode they cover why lifting weights twice a week is already getting most of the available benefit and three times is better but not by as much as you think, why the hypertrophy rep range is far broader than the classic 8 to 12 and what that actually means for your training, why getting stronger still requires lifting heavy things regardless of what anyone tells you, how power training is about moving with intentional velocity and why it matters more as you age than most people realize, why periodization showed no statistically significant advantage over non-periodized programs in the systematic review and what that means in practice, why eccentrically biased training produces slightly better muscle growth but is an optimization tool not a fundamental one, why time under tension does not have the evidence base people think it does, why blood flow restriction remains a niche tool rather than a strategic advantage, and why the best workout is simply the one you will actually show up and do consistently.

The Docs Who Lift podcast distills and simplifies the complexities of exercise, medicine, and weight loss. Subscribe so you never miss an episode.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Spencer Nadolsky, Dr. Karl, and chief science officer Dr. Grant Tinsley sit down with Dr. Steven Heymsfield, physician at the Pennington Biomedical Research Center and lead author on the BELIEVE trial, to break down what happens when you combine bimagrumab with semaglutide and why over 90 percent of weight lost in the combination group was pure fat. Dr. Heymsfield has published over 600 peer reviewed articles and is widely considered one of the foremost body composition researchers in the world, and Grant Tinsley credits him as a foundational influence on his own work in the field.

In this episode they cover what bimagrumab actually is and how blocking the activin receptor causes muscle to grow, the origin story of the drug from Novartis to Versanus to Lilly and why sarcopenia research accidentally opened the door to obesity treatment, the nine group trial design and what it really boils down to, why the bimagrumab only group lost 7 percent of their weight entirely as fat without reducing food intake, the LDL cholesterol finding that has everyone talking and whether it actually matters, what happens to muscle and weight when you come off both drugs, why visceral adipose tissue practically disappeared in the antibody treated groups, the functional outcomes data including grip strength and physical activity scales, whether a subcutaneous version is coming, and what the future of this drug class looks like now that Lilly has deprioritized it.

The Docs Who Lift podcast distills and simplifies the complexities of exercise, medicine, and weight loss. Subscribe so you never miss an episode.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Spencer and Karl Nadolsky bring on Dr. Alyssa Olenick, exercise physiologist and postdoctoral researcher in menopause and metabolism, to cut through the noise on one of the most misrepresented topics in women's health.

Dr. Olenick holds a PhD in exercise physiology, completed postdoctoral training focused on menopause and body composition, and is the founder of the Liss Method, a hybrid training program combining strength and endurance. She has been doing women-specific and sex-difference research since her master's degree and is one of the sharper voices pushing back on the wave of pseudoscience targeting women in the fitness space.

In this episode they cover what actually changes in body composition during the menopausal transition and what does not, why fitness status matters more than menstrual cycle phase or contraceptive use, how the fitness industry profits from pinkifying advice that was never women-specific to begin with, the truth about rep ranges and why effort matters more than the number, cortisol myths and why the adaptive stress response to exercise is not your enemy, and how to approach training adjustments during perimenopause without overcorrecting into low intensity fear-based programming.

No pseudoscience. No pink packets. Just the research.
Follow Dr. Olenick Here

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Takeaways:

Creatine is a naturally occurring compound that helps regenerate ATP, the energy currency of the cell.

Supplementing with creatine can enhance performance in high-intensity exercise but may not be beneficial for endurance activities.

The majority of creatine is stored in muscle, and supplementation can help fill those stores for better energy availability.

Creatine monohydrate is the most studied and effective form of creatine, and it's also the cheapest.

There is no need to cycle creatine; continuous use is safe and effective.

Creatine supplementation is generally safe, but individuals should inform their healthcare providers about its use.

The benefits of creatine are most pronounced in individuals engaging in high-intensity exercise.

Creatine does not directly build muscle; it requires exercise to be effective.

There is a misconception that creatine is harmful to the kidneys; it is safe for healthy individuals.

Creatine supplementation may have potential cognitive benefits, but more research is needed.

Follow Dr. Lauren

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Takeaways:
The 11-Minute Rule: Why blue light isn't the villain you think it is.

The Melatonin Mistake: Why "less is more" (and the exact dosage for success).

Trackers vs. Reality: When to throw away your Apple Watch or Oura Ring.

The Bedrock Principle: Why sleep is the lead domino for fat loss and metabolic health.

Sex & Sleep: The surprising biological difference in how men and women recover.

Tap Here to follow Shelby

Shelbys Book

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Get The Lucky Egg Book Here

Takeaways:

Dr. Lucky Sekhon is a reproductive endocrinologist and author of 'The Lucky Egg'.

The pathway to reproductive endocrinology involves extensive training in OB-GYN and specialized fellowship.

Social media became a tool for Dr. Sekhon to combat misinformation during the pandemic.

Common myths in fertility include the idea that one can reverse the biological clock.

Understanding the fertility knowledge gap is crucial for patients seeking help.

Insulin resistance plays a significant role in fertility issues, especially in women with PCOS.

Fertility treatments should be evidence-based and tailored to individual needs.

GLP-1 medications can help regulate menstrual cycles and improve fertility outcomes.

Endometriosis can significantly impact fertility and requires tailored treatment approaches.

The importance of patient education in navigating fertility treatments cannot be overstated.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Takeaways

Excellence is not a standard but a process of becoming.

Involved engagement means caring deeply about what you do.

The pursuit of excellence shapes you into a better person.

Consistency is key to achieving long-term goals.

It's important to align your pursuits with your values.

Youth sports can be beneficial but also harmful if not approached correctly.

Weight loss should shift from a focus on numbers to health and well-being.

Building a diverse identity can help prevent burnout in athletes.

The transition out of sports can be challenging due to identity loss.

Enjoying the process is more fulfilling than the end goal.

Tap or Click Here to Buy Brads Book

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Key Episode Takeaways

Oral Wegovy is real, but it’s not “just a pill version of the shot.” Absorption rules, dosing schedules, and patient selection matter a lot more than most headlines suggest.

Switching from injections to oral GLP-1s requires a plan. The transition isn’t one-size-fits-all, and dose timing, GI tolerance, and expectations need to be managed carefully.

Weight regain after stopping GLP-1s is common, but not universal. SURMOUNT-4 data shows large variability, reinforcing that biology, not willpower, drives outcomes.

Maintenance matters as much as weight loss. Some patients need continued therapy at lower doses, while others may maintain with lifestyle plus strategic medication use.

Stopping abruptly is usually the worst approach. Gradual transitions and realistic long-term strategies reduce rebound weight gain.

GLP-1s are chronic disease tools, not short-term fixes. Treating obesity like hypertension or diabetes leads to better outcomes and fewer surprises.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Takeaways:

Dietary guidelines have evolved since the 1980s.

The food pyramid was introduced in 1992 and has influenced public perception.

New dietary guidelines emphasize healthy fats but retain some old recommendations.

There are contradictions in the new guidelines regarding saturated fat and protein intake.

The definition of processed foods remains vague and controversial.

The guidelines are intended for healthcare professionals, not consumers.

Public policy needs to align with dietary guidelines for effective implementation.

The emphasis on real food is not a new concept in dietary guidelines.

There is skepticism about whether the new guidelines will lead to meaningful changes in public health.

The conversation around dietary guidelines is often politically charged.

Follow Kevin: Tap Here

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Takeaways:

Cortisol is essential for various bodily functions, especially during stress.

Adrenal glands have a circadian rhythm that affects cortisol production.

Cushing's syndrome can result from excess cortisol and has specific symptoms.

Diagnosis of adrenal disorders requires careful testing and consideration of symptoms.

Mild autonomous cortisol secretion can complicate diabetes management.

The Catalyst trial explored the effects of cortisol antagonism on diabetes.

Future research may focus on selective glucocorticoid receptor modulators.

Woolly mammoth studies provide insights into historical testosterone levels.

Understanding adrenal health is crucial for effective patient care.

Endocrinologists must navigate the complexities of hormone testing and treatment.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Takeaways:

Slimmer's Paralysis is a recognized condition.

Ethical boundaries are crucial in patient relationships.

Medical professionals must maintain professionalism at all times.

Humor can sometimes arise in serious discussions.

Patient stories should always be handled with care.

The importance of clear communication in medical settings.

Understanding patient experiences is vital for effective care.

Ethics in medicine is a complex and nuanced topic.

Medical discussions can lead to unexpected topics.

Maintaining a professional demeanor is essential.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Takeaways:

Drug transfer during lactation is complex and challenging.

Semaglutide was not detected in women taking any dose.

Low amounts of tears epitide were found in milk.

Tissue damage can affect drug absorption.

Mastitis and engorgement complicate the lactation process.

Injections are necessary for effective drug delivery.

The analogy of an elephant illustrates the difficulty of drug transfer.

Detection of drugs in milk is a critical concern for breastfeeding mothers.

Understanding turnover is essential in lactation studies.

The implications of drug transfer on women's health are significant.

Infant Risk Center Link

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Takeaways:

Behavior change is a complex process that requires understanding motivation and discipline.

Motivation is not just a feeling; it's a psychological skill that can be developed.

Many common phrases about behavior change are misleading and oversimplified.

Exercise should be viewed as a choice rather than a habit that becomes automatic.

Self-efficacy is crucial for successful behavior change and can be built through mastery experiences.

Future self thinking can help individuals align their actions with their long-term goals.

It's important to lower barriers to entry for new behaviors to increase adherence.

Modeling healthy behaviors is essential for influencing children and adolescents.

The psychological definition of a habit differs from the colloquial use of the term.

Resources and support systems are vital for individuals looking to change their behaviors.

Follow Dr. Nordin Here

https://bodybrainalliance.com/

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

• Testosterone therapy can improve libido in postmenopausal women.
• Sexual dysfunction in women is complex and multifactorial.
• Low sexual desire is only considered a disorder if it causes distress.
• Psychosocial factors play a significant role in sexual health.
• Testosterone levels do not change significantly at menopause.
• The placebo effect can significantly influence treatment outcomes.
• Individualized care is crucial in managing sexual dysfunction.
• Dosing for testosterone therapy should be carefully monitored.
• Current medications for low libido have modest benefits.
• Evidence for testosterone therapy in premenopausal women is still emerging.
  
  Tap to Follow Dr.Susan

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Show Notes:
In this episode of Docs Who Lift, the Nadolsky brothers welcome back Dr. Sean Wharton, clinical trialist and one of the leading researchers behind the next generation of oral GLP-1 medications. Together, they break down:

The OASIS-4 trial results on 25mg oral semaglutide and how it stacks up to injectable Wegovy

How orforglipron, Eli Lilly’s new small-molecule GLP-1, differs from peptide-based drugs

Why these new therapies could make weight management more accessible and affordable

The fascinating pharmacology behind “snack molecules” and small-molecule receptor agonists

Common misconceptions about bioavailability, dosing, and side effects

The potential role of oral GLP-1s for patients with mild obesity or cardiometabolic disease

Whether you’re a clinician, researcher, or patient curious about the future of obesity medicine, this conversation offers a clear look at how science is shifting toward needle-free solutions.

Oasis 1 Trial Link

Oasis 4 Trial Link

Attain 1 Trial Link

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Docs Who Lift, the Nadolsky brothers dive deep into the newly released American Association of Clinical Endocrinology (ACE) Algorithm for Obesity Care led by Dr. Karl himself. They explore:

Why ACE moved away from a BMI-only approach to a person-centered, complication-centric model

The new staging framework (ABCD) that helps individualize treatment intensity

How to interpret “clinical” vs “preclinical” obesity under the new model

Updated targets for clinically meaningful weight loss (5%, 10%, 15% tiers)

The emphasis on resistance training, sleep, and behavioral health alongside nutrition

Practical guidance for selecting anti-obesity medications and identifying the right therapy for each patient

Whether you’re a clinician, health professional, or patient trying to understand modern obesity care, this episode breaks it all down in a practical, real-world way without the jargon.

Youtube Video to follow along the graphic mentioned

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Takeaways

• The book aims to dispel myths surrounding the Biggest Loser study.
• Miscommunication in media has led to public confusion about metabolism.
• Metabolic adaptation is a response to weight loss, not a determinant of it.
• Cultural factors significantly influence eating habits and food choices.
• The food environment plays a crucial role in dietary behaviors.
• Bipartisan support is necessary for effective food policy changes.
• Understanding metabolism requires a nuanced approach beyond just calories.
• The relationship between exercise and metabolism is complex and not fully understood.
• Appetite signals are a major factor in weight regain after dieting.
• Education about nutrition science is essential for public understanding.
  
  Julia Belluz X/Twitter
  Kevin Hall X/Twitter
  Purchase Their Book Here
  
  
  
  
  
  
  
  
  
   

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Takeaways

Menopausal women often prioritize weight gain concerns over other symptoms.

The study observed an association between hormone therapy and weight loss with GLP-1 medications.

Retrospective studies have limitations but can provide valuable insights.

Future research should focus on randomized controlled trials to confirm findings.

The relationship between estrogen and GLP-1 signaling needs further exploration.

Funding for research can be challenging, especially for early career investigators.

Collaboration between different specialties is crucial for comprehensive patient care.

The media often misrepresents research findings, leading to misconceptions.

Individualized treatment plans are essential for menopausal women.

There is a need for more awareness about the effects of menopause on health.

Research Links:
Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use
Combination of obesity medication tirzepatide and menopause hormone therapy fuels weight loss



 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

We covered:

Fasted training

Protein timing

and many more fitness topics!

Hear Dr. Lauren Colenso-Semple and Dr. Stacy Sims discuss outcomes versus mechanisms and much more

Tap Here for Dr Stacy Sims References
Tap Here for Dr. Colenso-Semples References

Dr. LCS Instagram
Dr. SS Instagram

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Takeaways

• The podcast features Dr. Grant Tinsley, a body composition expert.
• The discussion revolves around a case series on body composition effects.
• GLP-1 receptor agonists are a focus of the research.
• The importance of resistance training in weight loss is emphasized.
• Patient case studies provide insights into individual experiences.
• The first patient lost a significant amount of fat mass while preserving lean mass.
• The second patient achieved remarkable body composition changes in a short time.
• The third patient showed positive changes over a longer duration.
• The need for more randomized trials is highlighted.
• The conversation underscores the role of exercise and nutrition in weight management.
  
  Tap or Click here to see more from Dr. Grant
  Tap here for scientific references in this episode.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Takeaways

Direct-to-consumer lab testing is on the rise, with significant marketing efforts behind it.

Many patients feel brushed off by traditional healthcare providers, leading them to seek alternative testing options.

Communication between patients and healthcare providers is often inadequate, contributing to misunderstandings about health.

Over-testing can lead to unnecessary anxiety and misinterpretation of results.

Fitness influencers often promote lab testing without proper medical training, which can be harmful.

There is a need for ethical practices in lab testing and patient care.

Patients should be cautious of companies that upsell supplements based on lab results.

The healthcare system often fails to provide adequate time for patient concerns to be addressed.

Understanding lab results requires skilled interpretation, which is often lacking in direct-to-consumer models.

A collaborative approach among healthcare professionals is necessary to improve patient outcomes.

Click to join Dr. Spencer's online clinic if you need help with this 
 

Click here to check out Barbell Medicine

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of the Dr. Lift podcast, hosts Dr. Spencer Nadolsky and Dr. Karl discuss the recent changes in obesity medication coverage, particularly focusing on the CVS Caremark decision to drop ZEPBound from their formulary in favor of Wegovi. They explore the implications of this decision for patients and providers, the role of pharmacy benefit managers (PBMs) in healthcare, and the ongoing advocacy efforts to ensure access to effective obesity treatments. The conversation highlights the complexities of insurance coverage, the need for patient-centered care, and the importance of making medications more affordable.

- The recent changes in obesity medication coverage have raised concerns among providers and patients.

- CVS Caremark's decision to drop ZEPBound has sparked a petition advocating for better access to medications.

- Pharmacy Benefit Managers (PBMs) play a significant role in determining medication coverage and costs.

- There is a need for more nuanced insurance policies that consider patient needs and clinical severity.

- Advocacy efforts are crucial in reversing negative trends in medication coverage.

- Patients often face challenges with prior authorization processes when switching medications.

- The cost of obesity medications is a significant barrier to access for many patients.

- Insurance companies are increasingly dropping coverage for anti-obesity medications, impacting patient care.

- The conversation emphasizes the importance of patient-centered care in obesity treatment.

- There is a call for making obesity medications more affordable and accessible to patients.

https://www.change.org/p/stop-cvs-caremark-s-zepbound-ban-restore-coverage-of-the-superior-obesity-medication

Click to join Dr. Spencer's online clinic if you need help with this 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of the Dr. Lift podcast, hosts Dr. Spencer Nadolsky and Dr. Karl discuss the Surpass CVOT trial, which evaluates the cardiovascular outcomes of Monjaro compared to Dulaglutide (Trulicity). They delve into the significance of the trial, the implications of the results, and the potential benefits of Monjaro for patients with type 2 diabetes and cardiovascular risks. The conversation highlights the importance of understanding cardiovascular outcome trials and the evolving landscape of diabetes medications.

Takeaways: 

The Surpass CVOT trial compares Mounjaro to Dulaglutide.

Dulaglutide has shown cardiovascular benefits in previous trials.

The trial results indicate Monjaro is at least not inferior to Dulaglutide.

There is a trend towards better cardiovascular outcomes with Mounjaro.

Weight loss and glycemic control are significant benefits of Mounjaro.

The trial did not include a placebo, but used a putative analysis.

The results are reassuring for patients at high cardiovascular risk.

The conversation emphasizes the importance of comprehensive treatment for metabolic diseases.

The hosts express enthusiasm for the potential of Mounjaro.

Future discussions will delve deeper into the trial's findings.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

How the STEP-UP trial came to life,  and what made the 7.2mg dose possible

What the data actually says about weight loss and side effects at higher doses

Why trial design, pharmacokinetics, and estimands matter more than you think

What’s coming next in obesity meds: duals, triples, and even antagonists

The real talk on intermittent fasting, access issues, and preaching vs. science

Sign up for Dr. Spencer''s Clinic

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Takeaways

• The study examines the overlap between clinical and anthropometric obesity.
• Anthropometric measures include waist circumference, waist-to-hip ratio, and BMI.
• Challenges exist in applying the Lancet Commission's definitions in clinical practice.
• Metabolically healthy obesity is a debated topic in obesity research.
• The study highlights the importance of data from the All of Us Research Program.
• There is a significant prevalence of preclinical obesity in individuals with normal BMI.
• The classification of obesity may need to shift focus towards overweight individuals.
• The study's findings suggest a need for more nuanced definitions of obesity-related diseases.
• Future research will explore the transition from preclinical to clinical obesity.
• The conversation emphasizes the importance of real-world data in understanding obesity.

Click here to see the study

Follow Dr. Yao on X here

Follow Dr. Blaha on X here 

Click here to join Dr. Spencer's online clinic

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Learn what age-related macular degeneration (AMD) is

What causes AMD

The types of AMD

The update on NAION - listen to last year's podcast all about it

Why we aren't too concerned

Click here to join Dr. Spencer's online clinic Vineyard

Click to read the JAMA AMD article

Click to read the Ophthalmology journal AMD article

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

• Menopausal hormonal therapy should not be a blanket recommendation for everyone going through menopause
• Weight management in women is influenced by hormonal changes throughout life stages.
• Retrospective analyses can provide insights but have limitations.
• The wellness industry often oversimplifies complex medical issues.
• Hormonal replacement therapy may have subtle benefits for weight management.
• Confounding factors like SSRIs can complicate weight loss efforts.
• A holistic approach is essential for managing women's health during menopause.
• Education and awareness are crucial for women navigating menopause.
• Future research should focus on randomized controlled trials for better clarity.
• Understanding individual patient experiences is key to effective treatment.

Click here to see her study

Click here to follow Dr. Tchang on X

Click here to join Dr. Spencer's clinic Vineyard 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

• Dr. Grant Tinsley joins the discussion as the body composition expert.
• Myostatin is a key regulator of muscle growth.
• Wendy Whippete the most jacked muscled up dog
• The concern of GLP-1 receptor agonists and muscle mass loss.
• Overview of Courage trial looking at semaglutide and trevogrumab and lean mass loss
• Upcoming Believe trial coming out (bimagrumab and semaglutide)
• Exercise remains crucial for muscle health and function.
• MRI data from SURPASS MRI provides new insights into muscle volume changes.
• The combination of medications may have varying effects on muscle mass.
• Caution is advised regarding the long-term effects of new drugs.
• Clinical benefits of medications often outweigh concerns about muscle loss.
• Future research will explore the synergy between exercise and medication.

Other docs who lift podcasts with Dr. Grant:

Tirzepatide muscle loss

Lean mass loss and GLP-1 meds

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Takeaways:

• The MAHA report aims to address public health issues but lacks actionable policies.
• Historical context is crucial for understanding current dietary guidelines.
• Funding for nutrition research has been inadequate, impacting the quality of data.
• Public perception of nutrition often outpaces scientific evidence.
• The evolution of dietary guidelines reflects political and social influences.
• There is a need for more rigorous nutrition science to inform policy.
• The dietary guidelines have not significantly improved population health metrics.
• Political will is essential for implementing effective nutrition policies.
• Nutrition science faces challenges in funding and research infrastructure.
• The MAHA report's recommendations may be more performative than substantive. Food policy changes are often superficial and ineffective.
• There is a significant disconnect between policy and actual health outcomes.
• Nutrition science is underfunded and lacks high-quality research.
• Misinformation in nutrition can lead to harmful public health outcomes.
• The focus on food additives distracts from more pressing issues like obesity.
• Experts are being sidelined in favor of political agendas.
• Public trust in health recommendations has eroded post-COVID.
• Nutrition policies need to be based on solid scientific evidence.
• The food industry needs clearer guidance on reformulating products.
• Future nutrition policies must prioritize public health over political gain

Read Dr. Kevin's paper

Follow Dr. Kevin on instagram

Join Dr. Spencer's clinic

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Click to read Joy Prescriptions

Drs. Karl and Spencer talk to Dr. Tiffany Moon all about Joy Prescriptions. Learn how to stop chasing perfection and embrace connection. 

00:00Introduction to Dr. Tiffany Moon

02:02Journey to Reality TV: The Real Housewives of Dallas

05:58Life After Reality TV: Finding Joy and Purpose

09:59The Joy Prescription: A New Approach to Life

17:01Work-Life Integration: Balancing Career and Family

22:09Empowering Women: The Lead Her Summit

22:33Tiffany's Journey: From Childhood to Medical Success

24:43The Quest for Joy: Breaking the Hedonic Treadmill

26:42Finding Gratitude and Connection in Life

28:37Coping Mechanisms: Humor and Self-Reflection

29:57The Joy Prescription: A Path for High Achievers

32:29Reconstructing Identity: Beyond External Validation

35:37The Impact of Sports on Identity and Achievement

40:54Closing Thoughts: Embracing Joy and Connection

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

• Tirzepatide is more effective for weight loss than semaglutide.
• Cost-effectiveness is crucial in prescribing weight loss medications.
• Patients with severe obesity should receive more expensive medications for better outcomes.
• Both medications show significant benefits for obesity-related conditions.
• Long-term studies indicate sustained weight loss with both drugs.
• Gender differences affect weight loss outcomes with these medications.
• Safety profiles show tirzepatide may be better tolerated than semaglutide.
• The need for affordable drug pricing is emphasized.
• Clinical benefits extend beyond weight loss to include metabolic health.
• Future studies are needed to confirm cardiovascular benefits of tirzepatide.

Click here to see the study

Click here to join Dr. Spencer's new online clinic

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Takeaways

• MASH is a significant obesity-related complication.
• Semaglutide shows promise in treating MASH.
• Weight loss is crucial for improving liver health.
• Bariatric surgery remains the most effective treatment.
• The Essence trial indicates a 63% resolution of NASH.
• New medications are being developed for obesity treatment.
• Early intervention is key to preventing severe liver damage.
• Accessibility of medications is a major concern.
• Comparative studies are essential for evaluating new treatments.
• Future treatments may include innovative delivery methods.

Chapters

00:00 Introduction to MASH and Semaglutide Study

04:29 Understanding Metabolic Dysfunction and Its Implications

08:02 Essence Trial: Semaglutide's Impact on MASH

12:58 Comparative Analysis of New Treatments for MASH

17:30 The Future of Obesity Treatment and Drug Accessibility

Join Vineyard - Dr. Spencer's online clinic

See the study

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Drs. Karl and Spencer chat with return guest Dr. Lauren Semple about creatine, protein, cortisol, fasting exercise, and training in women.

Follow Dr. Lauren's instagram

Join Dr. Spencer's online clinic

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Drs. Karl and Spencer discuss a new study looking at tirzepatide and metabolic rate. They also discuss a patient case of tirzepatide induced anhedonia.

Here is the tirzepatide study

If interested in joining Dr. Spencer's clinic Vineyard - Click Here

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Drs. Karl and Spencer discuss the claim that GLP-1 meds cause more fat cells.

Learn about if and how GLP-1 meds increase fat cells and what that means along with other claims about these medicine.

Join Dr. Spencer's online clinic that specializes in GLP-1 medicines

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Drs. Karl and Spencer talk to Dr. Kenneth Qiu all about direct medical care - the future of medicine.

Learn about how bypassing insurance and creating a relationship directly with a doctor can improve your health and save money in the long run.

Follow Dr. Qiu on Linked in

See Dr. Spencer's direct care model with Vineyard

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Drs. Karl and Spencer discuss with Dr. Grant Tinsley all about the new analysis of how much "lean mass" is lost with tirzepatide, the most powerful medicine available for weight loss.

Learn:

The difference between fat free mass and lean mass and lean soft tissue and muscle.

If GLP-1 medicines cause muscle loss specifically

How to minimize muscle loss when taking these medicines

Our new study together.

Click here for the tirzepatide paper

Click here to see Dr. Grant Tinsely's Instagram

Click here to join Vineyard

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Drs. Karl and Spencer discuss how bad the Hims and Hers ad was.

From an outside perspective, the ad may have seemed good.

But when you dig deeper, it was actually really bad.

Listen to learn.

Join Dr. Spencer's new online clinic - Vineyard.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.